# Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse

**Authors:** Nicolás Duque Clavijo, Juana Catalina Figueroa Aguirre, Claudia del Pilar Agudelo Lopez, Andrés Armando Borda, Beatriz Wills, Guillermo Enrique Quintero Vega

PMC · DOI: 10.3332/ecancer.2024.1717 · ecancermedicalscience · 2024-06-20

## TL;DR

This study shows that DLBCL prognosis in Bogotá is similar to high-income countries and identifies new markers for predicting survival and relapse in Hispanic patients.

## Contribution

The study identifies new prognostic markers for DLBCL in the Hispanic population, which are suitable for resource-limited settings.

## Key findings

- Patients with ki-67 ≥ 60% had a higher mortality risk, even after adjusting for IPI and B2-microglobulin.
- Absence of B symptoms was a protective factor for relapse when controlling for ki-67, CD5, and IPI.
- The 5-year OS rate in the cohort was comparable to that of high-income countries.

## Abstract

Diffuse large B-cell lymphoma (DLBCL), a prevalent non-Hodgkin lymphoma subtype, displays diverse clinical outcomes with persistently high mortality and relapse rates, despite treatment advancements. Notably, the Hispanic demographic lacks consideration in existing prognostic indices for DLBCL.

A retrospective cohort study encompassing 112 DLBCL patients diagnosed between 2010 and 2020 was conducted at our institution. Patient data, including overall survival (OS), treatment response, and relapse, were analysed.

With a median age of 65 years and a predominant male population (60.7%), both the International Prognostic Index (IPI) and revised IPI correlated with OS. In multivariate analysis, patients with ki-67 ≥ 60% exhibited higher mortality risk (Hazard Ratio: 2.35, 95% confidence intervals (CI) 1.05–5.27, p = 0.039), even when controlled by IPI category and B2-microglobulin levels. The absence of B symptoms served as a protective factor for relapse (p < 0.01, OR: 0.147, 95% CI 0.058–0.376) when controlling for ki-67, CD5, and IPI.

Our cohort demonstrated a 5-year OS rate comparable to high-income countries, highlighting the need for tailored prognostic models for Hispanic DLBCL patients. This study identifies easily accessible parameters aligning with regional resource constraints, providing insights into additional prognostic factors for DLBCL in the Hispanic population.

## Linked entities

- **Proteins:** Mki67 (antigen identified by monoclonal antibody Ki 67), CD5 (CD5 molecule)
- **Diseases:** Diffuse large B-cell lymphoma (MONDO:0018905), non-Hodgkin lymphoma (MONDO:0018908)

## Full-text entities

- **Genes:** HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}
- **Diseases:** DLBCL (MESH:D016403), non-Hodgkin lymphoma (MESH:D008228)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11254405/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11254405/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC11254405/full.md

---
Source: https://tomesphere.com/paper/PMC11254405